ACE genotype, risk and causal relationship to stroke: Implications for treatment |
| |
Authors: | Agnieszka Slowik MD PhD Tomasz Dziedzic MD PhD Joanna Pera MD PhD Dorota Wloch MD Grzegorz Kopec MD Andrzej Szczudlik MD PhD |
| |
Institution: | (1) Department of Neurology, Jagiellonian University, Medical College, Botaniczna 3, Kraków, 31-503, Poland |
| |
Abstract: | Opinion statement The angiotensin-converting enzyme (ACE) catalyzes the formation of angiotensin II and the breakdown of bradykinin into inactive
products. The insertion/deletion (I/D) polymorphism affects the activity of the enzyme, with the DD genotype being responsible
for the highest activity of the enzyme. Meta-analysis of 11 studies including white persons showed that the DD genotype was
a risk factor for ischemic stroke. No such correlation was found in an Asian population. Studies on different etiologies or
intermediate phenotypes of ischemic stroke did not bring univocal results. There are still no convincing data on whether the
I/D polymorphism of the ACE gene is a risk factor for spontaneous intracerebral hemorrhage and intracranial aneurysms, ruptured or unruptured. Several
pharmacogenetic studies analyzed the influence of the ACE I/D polymorphism on the response to acute stroke therapy (thrombolysis) or prevention strategies (lifestyle modification
and treatment of vascular risk factors). Presently, however, there is no consensus on whether the efficacy of these therapies
is affected by the ACE gene I/D polymorphism. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|